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METHOD OF MANUFACTURING 
ANAPLASMOSIS VACCINE 
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speaking, it is the object of this invention to provide an 
improved method of manufacturing anaplasmosis antigen 
and a vaccine from such antigen and including methods 
of utilizing such vaccine for the immunization of cattle. William Elihu Brock, Stillwater, and Charles Clifton 
Pearson and Ira Olin Kliewer, Pawhuska, Okla., 
assignors to Oklahoma State University of Agri-
culture & Applied Science, Stillwater, Okla., a 
corporation of Oklahoma 
5 More specifically, a primary object of the invention is to provide a method of manufacturing anaplasmosis anti-
gen. 
No Drawing. Filed June 23, 1965, Ser. No. 466,450 
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ABSTRACT OF THE DISCLOSURE 
This invention relates to a method of manufacturing 15 
and administering an anaplasmosis vaccine. More par-
ticularly, the invention includes the steps of exsanguinat-
ing an anaplasmosis infected bovine, centrifuging out the 
red blood cells obtained, ultrasonicating the cells to rup-
ture the cells to release anaplasma bodies therefrom with- 20 
out destroying such bodies, separating out the anaplasma 
bodies, freeze drying the anaplasma bodies, and mixing 
adjuvant with the freeze dry bodies. Inoculation of a 
bovine is achieved by subcutaneously injecting vaccine 
containing 10 milligrams of the freeze dryed anaplasma 25 
bodies. The inoculation is preferably repeated by a sec-
ond such injection six weeks to three months after the 
first injection. 
Another object of this invention is to provide a method 
of manufacturing an anaplasmosis vaccine. 
A further object of this invention is to provide a method 
of immunizing cattle against anaplasmosis. 
Further objects and advantages and a fuller under-
standing of the invention will become apparent from the 
following description and claims. 
Basically the invention can be divided into three inter-
dependent methods. The first, and most important, is a 
method of manufacturing anaplasmosis antigen. The sec-
ond is a method of preparing a vaccine from the obtained 
antigen. The third is a method of immunization utilizing 
the vaccine. 
Method of manufacturing anaplasmosis antigen 
The method of manufacturing anaplasmosis antigen 
according to this invention involves the sequential opera-
tion of eight basic steps which will be described in detail. 
Step one 
The first step is to obtain a quantity of anaplasmosis 
infected bovine whole blood. This is accomplished by 
This invention relates to a method of manufacturing 
anaplasmosis antigen. More particularly, this invention 
relates to a method of manufacturing anaplasmosis vac-
cine and use of the vaccine to immunize cattle. 
Anaplasmosis is an infectious disease of cattle which 
causes destruction of the red blood cells. The disease is 
caused by a minute parasite, Anaplasma marginale, which 
grows in the red blood cells of infected cattle. Anaplas-
mosis has been observed on all the continents of the world 
but it is a problem to cattlemen only in the warm, humid 
areas where certain insects that transmit the disease are 
numerous. The disease is primarily transmitted from in-
fected to healthy animals by insects such as horse flies, 
stable flies and mosquitoes and ticks, but may also be 
transmitted by unclean surgical instruments. 
30 exsanguinating a highly infected animal. In tests utilized 
to develop and prove the method of this invention this 
step consisted of first inoculating an anaplasmosis su'scep. 
tible splenectomized calf with ten mililiters of anaplas-
mosis carrier blood. When the maximum number of ana-
In the United States, anaplasmosis has been found in 
thirty-nine of the fifty states and is a major cause of eco-
nomic loss of cattle from anaplasmosis in approximately 
twenty states. Death losses in cattle from anaplasmosis 
a:re pres~ntlv about 48 to 50 million dollars a year in the 
"United States. An estimated 30 to 50 percent of the 
infected cattle die of the disease. Cattle that live through 
the disease lose weight, abort calves and recover from 
35 plasma infected red blood cells were present in the circu-
lation system of the calf, the calf was exsanguinated. All 
of the anaplasma infected cells were transfused into an 
adult cow. The cow was exsanguinated when the maxi-
mum number of anaplasma infected red blood cells were 
40 ?resent in her circulation system. Generally, in order for 
mfected blood to be at an efficient level for the manufac-
ture of antigen, the number of anaplasma infected red 
blood cells must be at least 2.0 X 106 per cubic millimeter 
of whole blood. While, as previously mentioned, in the 
45 development of the invention it was necessary, to facili-
tate the availability of sufficient quantities of highly in-
fected blood, to begin by inoculating anaplasmosis suscep-
tible calf, highly infected bovine blood from any source, 
whether from a naturally infected or an intentionally in-
50 fected cow or calf can serve as the source of raw material 
for the production of the antigen by the methods of this 
invention. 
the illness slowly over a two to three month period. 
Cattle that recover from anaplasmosis are carriers of the 
disease for the rest of their lives since their blood con- 55 
tinues to contain the Anaplasma marginale parasite. 
Step two 
The highly infected whole blood is then mixed with an 
anticoagulant to prevent clotting. Such anticoagulant may 
be of the known types, including citrate, oxalate or EDT A, 
or any other comparable anticoagulant useful for the 
purpose and known to the art. The anticoagulant is added 
for the purpose of maintaining the whole blood in liquid 
form. 
No completely successful treatment of cattle ill from 
anaplasmosis has been developed to date. Antibiotics such 
as aureomycin and terramycin are used in attempts to 
destroy the parasite in infected animals. Some veteri- 60 
narians use blood transfusions to replace the lost red 
blood cells in highly infected animals. Drugs to stimulate 
the production of new red cells are often given. Each of 
these methods as well as other methods of treating ana-
plasmosis are only partially successful and, as a result, the 65 
loss due to anaplasmosis has continued at a high rate. 
Programs have been undertaken to prevent anaplasmosis 
by such steps as careful insect control, care in the sani-
tization of dehorning and surgical equipment, and the 
isolation of known carrier animals. In spite of such pro- 70 
grams and the previous mentioned methods of treatment, 
the loss caused by anaplasmosis has continued. Generally 
Step three 
In this third step, the whole blood is centrifuged at a 
speed and time duration sufficient to cause the red blood 
cells to sediment. Care must be exercised in this step 
that the speed and duration of centrifugation is suffi-
cient to cause substantially complete sedimentation of 
the red blood cells (for efficient end product production) 
but at the same time the centrifugation must not be so 
great nor of such duration as to cause rupture of the 
cells. It has been found that centrifugation at a speed 
of approximately 500 gravities for a period of ten to 
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fifteen minutes produced proper sedimentation. The 
supernatant plasma obtained from the centrifugation is 
discarded and the sedimented red blood cells are used for 
the continuation of the steps of the method utilized in 
achieving the final antigen. 
Step four 
The red blood cells obtained as sediment from the 
centrifugation of step three are next suspended in a phys-
iologic saline solution. Such solution is known in the 
art and is composed of approximately 0.85% weight 
salt (NaCl) in distilled water. The purpose of this saline 
solution suspension is twofold, the first is to provide a 
fluid medium for the subsequent steps of the method 
and the second is to afford cleansing of the cells. 
Step five 
The suspended cell solution is ultrasonicated to rupture 
4 
cells are suspended in approximately two times their 
packed volume of saline solution preparatory to the ultra-
sonication of step five. 
Preparation of vaccine 
5 The vaccine is prepared by suspending the dried ana-
plasmosis antigen in an adjuvant. This may be accom-
plished easily when the antigen is stored in the sealed 
vials as previously mentioned by injecting into the vials 
the required amount of adjuvant to obtain the suspended 
10 fluid. Preferably, one to five milliliters of adjuvant is 
mixed with ten milligrams of dried antigen to produce 
the vaccine. 
The adjuvant utilized may be of several types includ-
ing light medicinal mineral oil or specially prepared ad-
15 juvants. 
Inoculation 
the cells and permit the exit therefrom of the included 
anaplasma bodies. Such ultrasonication was practiced in 20 
the development of the method of this invention by the 
use of a cooled constant flow Branson Sonicator. The 
apparatus must be operated at a rate to produce sub-
stantially complete rupture of all of the red blood cells 
without disintegration of the anaplasma bodies. The out-· 25 put of the ultrasonication step is a saline solution hav-
A variety of method of inoculation utilizing the vaccine 
of this invention have been investigated but it has been 
learned that the prefered method is to subcutaneously 
inoculate animals with one to five milliliters of vaccine 
containing ten milligrams of antigen prepared according 
to the previous disclosed method, followed by a second 
ten milligram inoculation at least six weeks but not more 
than three months after the first inoculation. A single 
inoculation utilizing a vaccine containing 250 milligrams 
of antigen has been found successful but prohibitively 
expensive. 
ing suspended therein ruptured red blood cells affording 
release of the included anaplasma bodies. 
Step six 
The suspended ruptured red blood cells are then cen-
trifuged to obtain sedimentation of the anaplasma bodies. 
Specifically, as practiced during development of the.meth-
od of this invention, a Sharples Constant Flow Centrifuge 
was utilized and was run at approximately 20,000 r.p.m. 
with a flow rate of suspended solution sufficient to sedi-
ment all the anaplasma bodies. Frequent microscopic 
examination of the supernatant fluid produced by the 
centrifugation was utilized to check the flow rate required 
to obtain substantially complete sedimentation. 
Step seven 
In the seventh step the supernatant fluid containing 
primarily the ruptured red blood cells suspended in the 
saline solution are discarded and the sedimented ana-
pla,sma bodies (antigen) are suspended in distilled water. 
A more particular practice of this step includes the ac-
curate proportioning of the quantity of distilled water 
used as a suspending medium to provide a suspended 
solution containing approximately 100 mg. of antigen 
(dried weight) per 10 milliliters of suspension. The selec-
tion of this proportion was for the purpose of providing 
accurate measurement of dosage aliquots. 
Step eight 
The final step in the basic process of manufacturing 
anaplasmosis antigen according to the system of this in-
vention is to freeze-dry (lyophilize) the suspended ana-
plasma bodies to obtain dried antigen. The method par-
ticularly used in the development and testing of this 
invention, and the method highly preferred, is to divide 
the suspended anaplasma bodies (antigen) obtained in 
step seven into vials so that each vial will contain the 
desired weight of dried antigen and freeze-dry the sus-
pended material in these vials. The vials are then vacuum 
sealed. These vacuum sealed vials of dried antigen may 
then be kept without freezing for a period of at least 
twelve months without impairing the effectiveness of the 
antigen. 
As previously mentioned with respect to step four, 
one of the reasons for suspending the red blood cells in 
a saline solution is to clean the cells. A preferred method 
is to sediment the red blood cells by centrifugation at 
least three times in saline solution to insure thorough 
cleaning of the cells and therefore a higher quality of 
Test results 
30 To test the effectiveness of the vaccine produced by the 
methods of this invention, an experimental group of 45 
uniform Hereford female two year old cows was selected. 
The cows were all tested by the complement-fixation test 
for anaplasmosis and were negative to the test before 
35 being placed in the experimental group. While the test 
involved the evaluation of various details not relevant to 
the basic methods of the invention, fundamentally the 
test included dividing the cattle into two groups, that is, 
a group inoculated by the vaccine manufactured by the 40 methods of this invention, and a non-vaccinated group. 
Later each of the test cows was injected with an equal 
amount of whole blood obtained from an anaplasmosis 
infected cow. Following inoculation with the infected 
blood, of the vaccinated group only 5.7 percent became 
45 sufficiently anemic to be moderately ill, 52.8 percent 
showed moderate anemia without illness, and 41.5 showed 
no anemia or illness. Of the unvaccinated group, all be-
came severely anemic and ill. 
An extremely important part of the invention is the 
50 discovery that two doses of 10 milligrams of antigen each 
suspended in 5 milliliters or less of adjuvant, administered 
at least six weeks apart, provides sufficient immunity to 
prevent death to cattle from anaplasmosis. The basic 
active ingredient of the vaccine is the antigen and, accord-
55 ing to the principles of this invention, each dose consists 
of at least approximately 10 milligrams of the antigen -
obtained by the steps described. The 10 milligrams of 
antigen is suspended in an adjuvant as a vehicle to facili-
tate inoculation and preferably one to five milliliters of 
60 adjuvant is used to suspend the 10 milligrams of antigen. 
This invention provides a means of manufacturing 
anaplasmosis antigen utilized to produce a vaccine whose 
success in producing immunity to anaplasmosis infection 
has been demonstrated in controlled tests. While the in-
65 vention has been described with a certain degree of par-
ticularity, it is manifest that many changes may be made 
in the methods, the sequence of steps, the interposition of 
additional and supplemental steps, and so forth, without 
departing from the spirit and scope of the invention which 
70 is set forth in the appended claims. 
What is claimed: 
1. A method of manufacturing anaplasmosis antigen 
comprising the steps of: 
the end product. Further, in the preferred method, the 75 




(b) mixing anticoagulant with the obtained blood; 
( c) centrifuging the anticoagulated blood to sediment 
the red blood cells without their rupture; 
(d) suspending the red blood cells in a physiologic 
saline solution; 
(e) ultrasonicating the suspended solution to rupture 5 
the red blood cells to release anaplasma bodies there-
from without destroying such bodies; 
(f) centrifuging the suspended solution to sediment the 
anaplasma bodies; 10 
(g) suspending the sediment anaplasma bodies in dis-
tilled water; and 
(h) freeze drying the ·suspended anaplasma bodies to 
obtain dried antigen. 
2. A method of manufacturing anaplasmosis antigen 15 
according to claim 1 wherein under step (g) the sediment 
anaplasma bodies are suspended at a ratio in distilled 
water to provide by step (h) approximately 100 milli-
grams of dried antigen per 10 milliliters of suspension. 
6 
(g) ultrasonicating the suspended solution to rupture 
the red blood cel!s to release anaplasma bodies there-
from without destroying such bodies; 
(h) centrifuging the suspended solution to sediment the 
anaplasma bodies; 
(i) suspending the sediment anaplasma bodies in dis-
tilled water; and 
(j) freeze drying the suspended anaplasma bodies to 
obtain dried antigen. 
5. A method of manufacturing anaplasmosis antigen 
according to claim 4 wherein steps (c) and (e) are re-
peated at least three times each to achieve thorough wash-
ing of the red blood cells. 
6. A method of manufacturing anaplasmosis antigen 
according to claim 4 including the step of suspending the 
dried antigen in an adjuvant to obtain an anaplasmosis 
vaccine. 
7. A method of manufacturing anaplasmosis antigen 
according to claim 4 wherein step ( c) consists of centri-
fuging the obtained blood at about 500 gravities for a 
period of from 10 to 15 minutes. 
3. A method of manufacturing anaplasmosis antigen 20 
according to claim 2 including dispensing the suspended 
anaplasma bodies obtained from step (g) into vials of 10 
milliliters aliquots each preparatory to freeze drying of 
step (h) and including the additional step of vacuum 
sealing the vials of dried antigen. 
4. A method of manufacturing anaplasmosis antigen 
comprising the steps of: 
(a) exsanguinating a bovine highly infected with ana-
plasmosis; 
8. A method of manufacturing anaplasmosis antigen 
according to claim 4 wherein under step (i) the sediment 
anaplasma bodies are suspended at a ratio in distilled 
25 water to provide by step (j) approximately 100 milligrams 
of dried antigen per 10 milliliters of suspension, and in-
cluding the steps of dispensing the desired amount of sus-
pended anaplasma bodies from step (i) into vials prepar-
(b) mixing anticoagulant with the obtained blood; 
( c) centrifuging the anticoagulated obtained blood to 
sediment the red blood celis without their rupture; 
(d) suspending the red blood cells in a physiologic 
saline solution; 
(e) washing the red blood cells in the saline solution 
by centrifugation to sediment the red blood cells 
therefrom; 
(f) resuspending the washed red blood cells in saline 
solution; 
30 atory to freeze drying of step (j) and vacuum sealing the 
vials of dried antigen. 
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